Kingdoms collide as bacteria and cells form captivating connections
Studying the pathogen R. parkeri, researchers discovered the first evidence of extensive and stable interkingdom contacts between a pathogen and a eukaryotic organelle.
A new computational model can predict antibody structures more accurately
Using this model, researchers may be able to identify antibody drugs that can target a variety of infectious diseases.
Noninvasive imaging method can penetrate deeper into living tissue
Using high-powered lasers, this new method could help biologists study the body’s immune responses and develop new medicines.
Cellular traffic congestion in chronic diseases suggests new therapeutic targets
Chronic diseases like diabetes are prevalent, costly, and challenging to treat. A common denominator driving them may be a promising new therapeutic target.
When a cell protector collaborates with a killer
New research reveals what it takes for a protein that is best known for protecting cells against death to take on the opposite role.
Seven with MIT ties elected to National Academy of Medicine for 2024
Professors Matthew Vander Heiden and Fan Wang, along with five MIT alumni, are honored for their outstanding professional achievement and commitment to service.
Pursuing the secrets of a stealthy parasite
By unraveling the genetic pathways that help Toxoplasma gondii persist in human cells, Sebastian Lourido hopes to find new ways to treat toxoplasmosis.
AI model identifies certain breast tumor stages likely to progress to invasive cancer
The model could help clinicians assess breast cancer stage and ultimately help in reducing overtreatment.
CHARMed collaboration creates a potent therapy candidate for fatal prion diseases
A new gene-silencing tool shows promise as a future therapy against prion diseases and paves the way for new approaches to treating disease.
Symposium highlights scale of mental health crisis and novel methods of diagnosis and treatment
Co-hosted by the McGovern Institute, MIT Open Learning, and others, the symposium stressed emerging technologies in advancing understanding of mental health and neurological conditions.
Taking RNAi from interesting science to impactful new treatments
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
New treatment could reverse hair loss caused by an autoimmune skin disease
A microneedle patch that delivers immune-regulating molecules can teach T cells not to attack hair follicles, helping hair to regrow.
Epigenomic analysis sheds light on risk factors for ALS
In a study of cells from nearly 400 ALS patients, researchers identified genomic regions with chemical modifications linked to disease progression.
3 Questions: A shared vocabulary for how infectious diseases spread
Lydia Bourouiba’s research on fluid dynamics influenced new guidance from the World Health Organization that will shape how health agencies respond to respiratory infectious diseases.
Improving drug development with a vast map of the immune system
Immunai’s founders were researchers at MIT when they launched their company to help predict how patients will respond to new treatments.